ArticleUrolithiasis2025
GGT1 protects against calcium oxalate crystal-induced renal tubular epithelial cell injury by targeting GCLC.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nephrolithiasis is a prevalent urological disorder in which calcium oxalate (CaOx) stones are most common, and accumulating evidence suggests that oxidative stress and ferroptosis contribute to CaOx-induced tubular epithelial injury. In this study, glyoxylic acid–induced mouse nephrocalcinosis and CaOx-stimulated HK-2 cells were used to explore the role of gamma-glutamyltransferase 1 (GGT1), a key enzyme in glutathione metabolism. RNA sequencing and qRT-PCR analyses identified GGT1 as a significantly downregulated gene in both models, and bioinformatic prediction followed by molecular validation demonstrated its interaction with the glutamate-cysteine ligase catalytic subunit (GCLC). GGT1 overexpression enhanced SLC7A11 and GPX4 expression while suppressing ACSL4, thereby reducing lipid peroxidation, mitigating oxidative stress, and alleviating tubular injury, whereas co-silencing GCLC attenuated these protective effects. These findings reveal that GGT1 safeguards against CaOx-induced nephrotoxicity by targeting GCLC to regulate ferroptosis and highlight GGT1 as a potential therapeutic target in nephrolithiasis.
Indexed as
Identifiers
41441879What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.